VXRT - Earnings announcements

Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) today announced that members of the Company's senior management team will participate in a virtual fireside chat on Friday, May 8, 2026 at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the first quarter ended March 31, 2026, after the market close on Thursday, May 7, 2026. The live fireside chat can be accessed by clicking here or on the Company's website at www.vaxart.com. Investors may submit written questions in ad

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clin

Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will host two upcoming webcast conference calls. Full Year 2025 Business Update and Financial ResultsVaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. / 1:30 p.m. PT. The full year financial resul

Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, demonstrating potential for improved protection against infection; Company continues to explore partnership opportunities Cash, cash equivalents and investments of $

Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart") today announced it will host two upcoming webcast conference calls. Third Quarter 2025 Financial ResultsVaxart will provide a business update and report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The third quarter financial results conference call can be a

HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 millionBoard of Directors authorizes new $100 million share repurchase program Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunitiesConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vacc

- ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock split proposal - - Webcast to begin at 4:30 p.m. ET / 1:30 p.m. PT - SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the senior management team will participate in a virtual stockholder fireside chat on Wednesday, August 20, 2025 at 4:30 p.m. ET / 1:30 p.m. PT. "Our leadership team is excited for this opportunity to connect with our stockholders directly. This fireside chat is a chance for

Reported positive topline data from Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection    Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled on August 20, 2025 at 4:30 p.m. ET to answer frequently asked questions in advance of Special Meeting of Stockholders

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, after the market close on Wednesday, August 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, August 13, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13755103 Investors may submit written questions in advance of the conference c

- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection - - Vaccine candidates were safe and well-tolerated across all dose groups with no vaccine-related serious adverse events reported - - Conference call today at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported positive t

SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International:

Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025 New avian influenza vaccine candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals Jeroen Grasman appointed as Chief Financial Officer effective May 19, 2025 Cash, cash equivalents and investments of $41.9 million as of March 31, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 13, 2025 (

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Tuesday, May 13, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13753354 Investors may submit written questions in advance of the confer

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the full year 2024. "Since our founding, Vaxart has been on a mission to transform glo

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2024 after the market close on Thursday, March 20, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, March 20, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13751819 Investors may submit written questions in advance of the conference call

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the third quarter of 2024. "Our successful initiation of sentinel cohort dosing is a testament to our rapid execution in helping to ensure that we remain on track to meet the milestones of our Biomedical Advanced Research Development Authority (BARDA) contract," said Steven Lo, Vaxart's Chi

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, November 13, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13749666 Investors may submit written questions in advance of

        BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats Solid financial position enables Vaxart to execute on multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the second quarter of 2024. "We achieved meaningful progress on our clinical, regulatory and operational goals during the first half of 2024," said Steven Lo, Vaxart's Chief Executive Officer. "Most s

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursday, August 8, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, August 8, 2024 – 4:30 p.m. ETDomestic: (866) 682-6100International: (862) 298-0702Conference ID: 13747081 Investors may submit written questions in advance of the conference call

     Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart's oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator as early as the second quarter of 2024 Anticipates meeting with the FDA in mid-2024 to evaluate clinical data and discuss next steps for its norovirus program Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the first quart

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2024 after the market close on Monday, May 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Monday, May 13, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13745591 Investors may submit written questions in advance of the conferenc

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, March 14, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13744368 Investors may submit written questions in advance of the conference call to ir@vaxart.com. A repla

Norovirus challenge study topline results indicate the potential of Vaxart's oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding Clinical proof of concept for the Company's oral pill vaccine platform now established in two human challenge studies for norovirus and influenza Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the third quarter of 2023. "During the third quarter, we took important steps toward validating our mucosal vaccine platform with the release of topline data from

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2023 after the market close on Thursday, November 2, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, November 2, 2023 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13741880 Investors may submit written questions in advance of the conferen

Study met 5 of 6 primary endpoints Vaccine was safe and well tolerated with no vaccine-related serious adverse events (SAEs) Vaccination led to a statistically significant reduction in infection rate, a non-statistically significant reduction in norovirus acute gastroenteritis (AGE), and a substantial reduction in viral shedding Conference call today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced top-line data from the Phase 2 challenge study of its oral tablet monovalent norovirus vaccine candidate (NCT05212168). The Phase 2 challenge study enrolled 165 healthy adults, who were randomized 1:1 to receive Vaxa

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, August 3, 2023 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13739413 Investors may submit written questions in advance of the conference call

On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the first quarter of 2023. "During the first quarter, we continued to advance our norovirus oral pill vaccine program and remain on track to report two important clinical data readouts in 2023," said Andrei Floroiu, Vaxart's Chief Executive Officer. "Norovirus represents a significant public health issue with no approved vaccine, and it places a treme

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 4, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, May 4, 2023 – 4:30 p.m. ETDomestic: (888) 272-8703International: (713) 481-1320Conference ID: 13737884 A replay of the webcast will be available on the Company's web

Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance cross-reactivity and potency with the goal of developing a pan-betacoronavirus vaccine Portfolio prioritization extends cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) issued its business update today for the full year 2022, during which Vaxart announced it is prioritizing development of the Company's bivalent norovirus candidate. "After completing six norovirus clinical trials, we are encou

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednesday, March 15, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, March 15, 2023 – 4:30 p.m. ETDomestic: 888-407-0832International: 201-689-8433Conference ID: 13735958 A replay of the webcast will be available on the Company's website

Growing body of clinical evidence supports transformational potential of Vaxart's oral vaccine platform Clinical trial programs on track for reporting key data milestones Ended third quarter with $114.8 million in cash, cash equivalents and marketable securities Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) issued its business update today for the third quarter of 2022, during which the Company made significant progress on its oral vaccine candidates. "We are encouraged by the growing body of clinical evidence that supports the transformational potential of Vaxart's oral pill vaccine platform with positi

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Tuesday, November 8, 2022 – 4:30 p.m. ETDomestic: 888-437-3179International: 862-298-0702Conference ID: 13733692 A replay of the webcast will be available on the Compan

— Study met primary safety and secondary immunogenicity endpoints — — Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects — — Elicited cross-reactive mucosal responses in approximately 50% of subjects — — Company to host conference call at 8:30 a.m. ET today — SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today reported positive top-line data from the first part of a planned two-part Phase II study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S. The data demonstrate that the trial met its primary safety and secondary immunogenicity endpoints and will inform ong

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022. The Vaxart senior management team will host a live conference call and webcast beginning at 8:30 a.m. Eastern Time on the same date to review the data and provide a trial update. Analysts and investors can participate in the conference call by dialing 877-407-0832 for domestic callers and 201-689-8433 for international callers, using the conference ID 13732510. Investors may submit written questions in a

Top-line data from COVID-19 Phase II study expected in the third quarter of 2022 Vaxart initiates work on vaccine candidates that directly target new omicron variants of concern Positive data from norovirus trial in elderly show similar immunogenicity to younger adults Ended second quarter with $131.5 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- In its business update today for the second quarter of 2022, Vaxart, Inc. (NASDAQ:VXRT) said it has begun working on vaccine candidate constructs that directly target new omicron variants of concern and is preparing to release top-line data in the third quarter of 202

SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2022 after the market close on Monday, August 8, 2022. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Monday, August 8, 2022 – 4:30 p.m. ETDomestic: 877-407-0832International: 201-689-8433Conference ID: 13731641 A replay of the webcast will be available on the Company's website at www.vaxart.com following the conclusion of the event.